Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Hemu (China) Biological Engineering

Request full access

Interventional medical devices for neurovascular and peripheral diseases

Weihai, ChinaFounded 2016

About Hemu (China) Biological Engineering

Hemu (China) Biological Engineering Co., Ltd. is a medical device company established in 2016, with formal operations beginning in 2017. The company was founded by Dr. Jack Wang (Wang Jicheng), an industry veteran with extensive experience in the medical device sector, including roles at Abbott and Johnson & Johnson, and as CEO of Biosensors International Group. His first entrepreneurial success was founding JW Medical Systems, which became one of China's top three developers of coronary drug-eluting stents, breaking foreign monopoly in the field.

The company focuses on designing, developing, and manufacturing innovative interventional medical devices for vascular diseases, particularly for the treatment of stroke. It provides comprehensive solutions for ischemic stroke, hemorrhagic stroke, and intracranial vascular stenosis. The firm operates on a global scale, with a Singapore headquarters, R&D centers in both Singapore and China, collaborations with labs in the U.S., and a production base in Weihai, Shandong province.

Hemu's product portfolio includes a range of devices for neurovascular and peripheral interventions. A key achievement was the 2021 launch of its Afentta™ intracranial thrombus aspiration catheter, the first such domestic device to receive approval from China's National Medical Products Administration (NMPA), addressing a significant market gap. Other commercialized products include the TracLine™ access catheter and the FocuStar neuro balloon catheter. The company has a deep pipeline with over a dozen products in preclinical stages and several others in clinical trials or under registration review. One of its peripheral non-vascular products is the Privi™ cooling balloon, a device for treating hemorrhoids through physical mechanisms.

Hemu generates revenue through the sale of its medical devices. The company has attracted significant investment from notable firms, including Hudson Bay Capital Management, OrbiMed, Lilly Asia Ventures, and Hillhouse Capital (Gao Ling Venture Capital), completing a Series C funding round of $50 million in late 2020.

Source: Dealroom company data

Hemu (China) Biological Engineering in the Weihai ecosystem

Live from Dealroom

The Hemu (China) Biological Engineering office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

Employees 10 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Hemu (China) Biological Engineering on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Hemu (China) Biological Engineering on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.